The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
暂无分享,去创建一个
D. Hill | T. Nicholas | D. Jennings | J. Seibyl | G. Stebbins | Z. Xie | K. Marek | D. Russell | J. Cedarbaum | D. Dexter | K. Romero | E. Somer | D. Grosset | M. Gordon | D. Stephenson | D. Matthews | Maria B. Tome | S. Vamvakas | D. Conrado | S. Imam | P. Maguire | Jill Gallagher | A. Roach | P. Basseches | Zhiyong Xie | Arthur Roach
[1] J. Cedarbaum,et al. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic , 2018, Movement disorders : official journal of the Movement Disorder Society.
[2] Martha Brumfield,et al. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease , 2014, Alzheimer's & Dementia.
[3] Dieter Deforce,et al. The European Medicines Agency experience with biomarker qualification. , 2015, Methods in molecular biology.
[4] David J. Brooks,et al. Molecular imaging of dopamine transporters , 2016, Ageing Research Reviews.
[5] Chris Leptak,et al. What evidence do we need for biomarker qualification? , 2017, Science Translational Medicine.
[6] W. Oertel,et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. , 2000, Movement disorders : official journal of the Movement Disorder Society.
[7] O. Hornykiewicz. Biochemical aspects of Parkinson's disease , 1998, Neurology.
[8] G. Rizzo,et al. Accuracy of clinical diagnosis of Parkinson disease , 2016, Neurology.
[9] S. Amur,et al. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization , 2015, Clinical pharmacology and therapeutics.
[10] D. Jennings,et al. Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease. , 2003, Advances in neurology.
[11] P B Hoffer,et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] H. Shill,et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease , 2014, Neurology.
[13] L. Pani,et al. The European Medicines Agency's strategies to meet the challenges of Alzheimer disease , 2015, Nature Reviews Drug Discovery.
[14] Koen Van Laere,et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[15] David J. Brooks,et al. Imaging biomarkers in Parkinson's disease , 2011, Progress in Neurobiology.
[16] John Seibyl,et al. SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0* , 2012, The Journal of Nuclear Medicine.
[17] Katie Kingwell. Zeroing in on neurodegenerative α-synuclein , 2017, Nature Reviews Drug Discovery.
[18] A. Singleton,et al. Finding useful biomarkers for Parkinson’s disease , 2018, Science Translational Medicine.
[19] J. Seibyl,et al. The role of the core imaging laboratory in multicenter trials. , 2010, Seminars in nuclear medicine.
[20] J. Seibyl,et al. 123I‐FP‐CIT SPECT [(123) I‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)‐N‐(3‐fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α‐synuclein Parkinson's disease cohort versus Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[21] CNS biomarkers: Potential from a regulatory perspective Case study – Focus in low hippocampus volume as a biomarker measured by MRI , 2015, European Neuropsychopharmacology.
[22] K. Kieburtz,et al. New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States , 2018, Movement disorders : official journal of the Movement Disorder Society.
[23] Claude Nahmias,et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.
[24] B. Bloem,et al. The Emerging Evidence of the Parkinson Pandemic , 2018, Journal of Parkinson's disease.
[25] Ian A. Watson,et al. Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis , 2017, Clinical and translational science.
[26] C. Tanner,et al. Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials , 2017, Movement disorders : official journal of the Movement Disorder Society.
[27] W. Rocca. The burden of Parkinson's disease: a worldwide perspective , 2018, The Lancet Neurology.
[28] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[29] Alberto J Espay,et al. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations , 2018, Movement disorders : official journal of the Movement Disorder Society.
[30] J. Seibyl,et al. Molecular Imaging Insights into Neurodegeneration: Focus on α-Synuclein Radiotracers , 2014, The Journal of Nuclear Medicine.
[31] Eugene M. Johnson,et al. MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE , 2008, Neurology.
[33] M. Frasier,et al. α-synuclein imaging: a critical need for Parkinson's disease research. , 2013, Journal of Parkinson's disease.
[34] S Fahn,et al. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. , 1999, Archives of neurology.
[35] A. Stoessl. Challenges and unfulfilled promises in Parkinson's disease , 2017, The Lancet Neurology.
[36] C. Adler,et al. Importance of low diagnostic Accuracy for early Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[37] C. Tanner,et al. Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[38] A. Lang,et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study , 2014, Neurology.
[39] D. Jennings,et al. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal Cohort , 2017, JAMA neurology.
[40] C. Adler,et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. , 2013, Brain : a journal of neurology.
[41] D. Turnbull,et al. Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?☆ , 2014, Ageing Research Reviews.
[42] A. Singleton,et al. The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.
[43] J. Cedarbaum. Elephants, Parkinson's Disease, and Proof‐of‐Concept Clinical Trials , 2018, Movement disorders : official journal of the Movement Disorder Society.
[44] D. Hill,et al. Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease , 2019, Clinical and translational science.
[45] Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease , 2007, Neurology.
[46] Arthur W. Toga,et al. Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease , 2015, Journal of Parkinson's disease.
[47] Nin Bajaj,et al. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[48] Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.
[49] D. Dickson,et al. Autosomal dominant Parkinson's disease caused by SNCA duplications. , 2016, Parkinsonism & related disorders.
[50] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[51] W. Westbroek,et al. Glucocerebrosidase is shaking up the synucleinopathies. , 2014, Brain : a journal of neurology.
[52] J. Jankovic,et al. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease , 2007, Neurology.
[53] J. Eberling,et al. A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein , 2018, Journal of Parkinson's disease.
[54] E. Masliah,et al. Therapeutic approaches in Parkinson's disease and related disorders , 2016, Journal of neurochemistry.
[55] Vincenzo Bonifati,et al. Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family. , 2015, Parkinsonism & related disorders.
[56] Susanne A Schneider,et al. What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[57] R. Postuma,et al. Insomnia and somnolence in idiopathic RBD: a prospective cohort study , 2017, npj Parkinson's Disease.